Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyo
Go back to Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyo| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 54.70 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.70 | 52 Week High | $77.12 | |||
| Open | $54.70 | 52 Week Low | $49.03 | |||
| Day High | $54.70 | P/E | 35.52 | |||
| Day Low | $54.70 | EPS | $1.54 | |||
| Volume | 15,795 | |||||
